Glycerol Phenylbutyrate

Active ingredient: Glycerol Phenylbutyrate

In short: Glycerol phenylbutyrate oral liquid is indicated for use as a nitrogen-binding agent for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. Glycerol phenylbutyrate oral liquid must be used with

Forms & strengthsOral liquid: colorless to pale yellow, 1.1 g/mL of glycerol phenylbutyrate (delivers 1.02 g/mL of phenylbutyrate).
LabelPAI Holdings, LLC dba PAI Pharma
Label updatedOct 26, 2026

What is Glycerol Phenylbutyrate used for?

Glycerol phenylbutyrate oral liquid is indicated for use as a nitrogen-binding agent for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. Glycerol phenylbutyrate oral liquid must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements).

Limitations of Use:

• Glycerol phenylbutyrate oral liquid is not indicated for the treatment of acute hyperammonemia in patients with UCDs because more rapidly acting interventions are essential to

reduce plasma ammonia levels.

• The safety and efficacy of glycerol phenylbutyrate oral liquid for the treatment of N-acetylglutamate synthase (NAGS) deficiency has not been established.

Glycerol Phenylbutyrate dosage

Glycerol phenylbutyrate oral liquid should be prescribed by a physician experienced in the management of UCDs.

Instruct patients to take glycerol phenylbutyrate oral liquid with food or formula and to administer directly into the mouth via oral syringe.

Instruct patients to use the glycerol phenylbutyrate oral liquid bottle and oral syringe as follows:

Use a new reclosable bottle cap adapter with each new bottle that is opened.

Open the glycerol phenylbutyrate oral liquid bottle and twist on the new reclosable bottle cap adapter.

Use a new and dry oral syringe to withdraw each prescribed dose of glycerol phenylbutyrate oral liquid.

Discard the oral syringe after each dose.

Tightly close the tethered tab on the reclosable bottle cap adapter after each use.

Do not rinse the reclosable bottle cap adapter.

Discard bottle and any remaining contents 28 days after opening.

If water or moisture enters the glycerol phenylbutyrate oral liquid bottle, the contents will become cloudy in appearance. If the contents of the bottle appear cloudy at any time, do not use the remaining glycerol phenylbutyrate oral liquid in the bottle and return it to the pharmacy to be discarded.

Instruct that glycerol phenylbutyrate oral liquid should be administered just prior to breastfeeding in infants who are breastfeeding.

For patients who cannot swallow, see the instructions on administration of glycerol phenylbutyrate oral liquid by nasogastric tube or gastrostomy tube .

For patients who require a volume of less than 1 mL per dose via nasogastric or gastrostomy tube, the delivered dose may be less than anticipated. Closely monitor these patients using ammonia levels .

The recommended dosages for patients switching from sodium phenylbutyrate to glycerol phenylbutyrate oral liquid and patients naïve to phenylbutyric acid are different . For both subpopulations:

Patients 2 years of age and older: Give glycerol phenylbutyrate oral liquid in 3 equally divided dosages, each rounded up to the nearest 0.5 mL

Patients less than 2 years: Give glycerol phenylbutyrate oral liquid in 3 or more equally divided dosages, each rounded up to the nearest 0.1 mL.

The maximum total daily dosage is 17.5 mL (19 g).

Glycerol phenylbutyrate oral liquid must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements).

Patients switching from sodium phenylbutyrate to glycerol phenylbutyrate oral liquid should receive the dosage of glycerol phenylbutyrate oral liquid that contains the same amount of phenylbutyric acid. …

How to take Glycerol Phenylbutyrate — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Neurotoxicity .

Inform patients/caregivers that adverse reactions of glycerol phenylbutyrate oral liquid are sometimes the same as symptoms of high blood ammonia. Neurological adverse reactions may also be associated with the major metabolite of glycerol phenylbutyrate oral liquid, PAA, and may be reversible.Blood tests for PAA may be done to measure the amount of PAA in the blood. Instruct the patient/caregiver to contact the healthcare provider immediately if the patient experiences: nausea, vomiting, headache, fatigue, somnolence, lightheadedness, confusion, exacerbation of preexisting neuropathy, disorientation, impaired memory, dysgeusia, or hypoacusis.

Lactation

Advise patients that breastfeeding is not recommended during treatment with glycerol phenylbutyrate oral liquid .

Administration

Instruct patients to take glycerol phenylbutyrate oral liquid with food or formula and to administer directly into the mouth via oral syringe. …

Warnings & precautions

Do not take this medicine if: Glycerol phenylbutyrate oral liquid is contraindicated in patients with known hypersensitivity to phenylbutyrate. Signs of hypersensitivity include wheezing, dyspnea, coughing, hypotension, flushing, nausea, and rash.

Increased exposure to PAA, the major metabolite of glycerol phenylbutyrate oral liquid, may be associated with neurotoxicity in patients with UCDs. In a study of adult cancer patients, subjects received sodium phenylacetate administered as a 1-hour infusion twice daily at two dose levels of 125 and 150 mg/kg for a 2-week period. Of 18 subjects enrolled, 7 had a history of primary central nervous system tumor. Signs and symptoms of potential PAA neurotoxicity, which were reversible, were reported at plasma PAA concentrations above 500 micrograms/mL and included somnolence, fatigue, lightheadedness, headache, dysgeusia, hypoacusis, disorientation, impaired memory, and exacerbation of preexisting neuropathy. PAA concentrations were not measured when symptoms resolved.

In healthy subjects, after administration of 4 mL and 6 mL glycerol phenylbutyrate oral liquid 3 times daily (13.2 g/day and 19.8 g/day, respectively) for 3 days, a dose-dependent increase in non- serious nervous system adverse reactions were observed. In subjects who had nervous system adverse reactions, plasma PAA concentrations, which were measured on Day 3 per protocol and not always at onset of symptoms, ranged from 8 to 56 micrograms/mL with 4 mL glycerol phenylbutyrate oral liquid 3 times daily and from 31 to 242 micrograms/mL with 6 mL glycerol phenylbutyrate oral liquid 3 times daily.

In clinical trials in patients with UCDs who had been on sodium phenylbutyrate prior to administration of glycerol phenylbutyrate oral liquid, adverse reactions of headache, fatigue, symptoms of peripheral neuropathy, seizures, tremor and/or dizziness were reported. …

Glycerol Phenylbutyrate side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

Neurotoxicity

Pancreatic insufficiency or Intestinal Malabsorption

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Assessment of adverse reactions was based on exposure of 45 adult patients (31 female and 14 male) with UCD subtype deficiencies of ornithine transcarbamylase (OTC, n=40), carbamoyl phosphate synthetase (CPS, n=2), and argininosuccinate synthetase (ASS, n=1) in a randomized, double-blind, active-controlled (glycerol phenylbutyrate oral liquid vs sodium phenylbutyrate), crossover, 4-week study (Study 1) that enrolled patients 18 years of age and older . One of the 45 patients received only sodium phenylbutyrate prior to withdrawing on day 1 of the study due to an adverse reaction.

The most common adverse reactions (occurring in at least 10% of patients) reported during short-term treatment with glycerol phenylbutyrate oral liquid were diarrhea, flatulence, and headache.

Table 1 summarizes adverse reactions occurring in 2 or more patients treated with glycerol phenylbutyrate oral liquid or sodium phenylbutyrate (incidence of at least 4% in either treatment arm). …

Drug interactions

Corticosteroids

Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Monitor ammonia levels closely when corticosteroids and glycerol phenylbutyrate oral liquid are used concomitantly.

Valproic Acid and Haloperidol

Hyperammonemia may be induced by haloperidol and by valproic acid. Monitor ammonia levels closely when use of valproic acid or haloperidol is necessary in patients with UCDs.

Probenecid

Probenecid may inhibit the renal excretion of metabolites of glycerol phenylbutyrate oral liquid including PAGN and PAA.

Drugs with narrow therapeutic index that are substrates of CYP3A4

Glycerol phenylbutyrate oral liquid is a weak inducer of CYP3A4 in humans. Concomitant use of glycerol phenylbutyrate oral liquid may decrease the systemic exposure to drugs that are substrates of CYP3A4. Monitor for decreased efficacy of drugs with narrow therapeutic index (e.g., alfentanil, quinidine, cyclosporine) .

Midazolam

Concomitant use of glycerol phenylbutyrate oral liquid decreased the systemic exposure of midazolam. Monitor for suboptimal effect of midazolam in patients who are being treated with glycerol phenylbutyrate oral liquid.

About this medicine

Glycerol phenylbutyrate oral liquid is a clear, colorless to pale yellow oral liquid. It is insoluble in water and most organic solvents, and it is soluble in dimethylsulfoxide (DMSO) and greater than 65% acetonitrile.

Glycerol phenylbutyrate is a nitrogen-binding agent. It is a triglyceride containing 3 molecules of PBA linked to a glycerol backbone, the chemical name of which is benzenebutanoic acid, 1′, 1′-(1,2,3-propanetriyl) ester with a molecular weight of 530.67. It has a molecular formula of C33H38O6. The structural formula is:

How it works: UCDs are inherited deficiencies of enzymes or transporters necessary for the synthesis of urea from ammonia (NH3, NH4 +). Absence of these enzymes or transporters results in the accumulation of toxic levels of ammonia in the blood and brain of affected patients. Glycerol phenylbutyrate is a triglyceride containing 3 molecules of PBA.

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 35855917-12cb-4c18-b7c5-5f275c1c80f0. Read the full official label on DailyMed.